{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"title":"Within 30 Days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"13"}]}],"title":"Within 60 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"description":"Number of deaths, regardless of cause, within 30 or 60 days from the first study dose divided by the total number of participants included in the Safety Analysis Set. Participants who died within 30 days were also included in the 60-day mortality calculations.","groups":[{"description":"Participants received Guadecitabine 60 mg/m\\^2, SC, on Days 1-5 of each 28-day cycle for at least 6 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy. Participants received Guadecitabine treatment beyond 6 cycles as long as the participant continued to benefit based on investigator judgment and participant response and tolerability (or up to a maximum of 36 cycles).","id":"OG000","title":"Guadecitabine"},{"description":"Participants received one of the three treatment choice options:\n\n1. LDAC 20 mg/m\\^2 SC/IV once daily for 14 days of each 28-day cycles for at least 4 cycles in absence of disease progression or unacceptable toxicity.Participants who were responding or had stable disease were to continue treatment as per standard institutional practice.\n2. Standard IC of a 7+3 regimen:Cytarabine 100-200 mg/m\\^2/day given as continuous infusion for 7 days and anthracycline(daunorubicin(45-60 mg)/idarubicin(9-12 mg)/mitoxantrone(8-12 mg)/m\\^2) by IV infusion for 3 days of each 28-day cycles.\n3. BSC as needed during the treatment included,but was not limited to,blood transfusions(RBCs or platelets),growth factors including erythropoiesis stimulating agents,granulocyte stimulating factors,iron chelating therapy,and broad-spectrum antibiotics and/or antifungals.\n\nDuration for treatment choice was as per locally approved prescribing information and institutional standard practice or up to a maximum 30 cycles.","id":"OG001","title":"Treatment Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set included all participants randomly assigned to study treatment who received any amount of study treatment or any component of a multi-dose study treatment regimen.","reportingStatus":"POSTED","timeFrame":"From first dose until 60 days after study treatment initiation","title":"30-day and 60-day All-cause Mortality","type":"SECONDARY","unitOfMeasure":"Participants"}